BioCryst Pharmaceuticals Files 8-K

Ticker: BCRX · Form: 8-K · Filed: Nov 4, 2024 · CIK: 882796

Sentiment: neutral

Topics: financial-reporting, operations

Related Tickers: BCRX

TL;DR

BioCryst dropped an 8-K on Nov 4th covering financials and operations.

AI Summary

BioCryst Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Durham, North Carolina.

Why It Matters

This 8-K filing provides crucial updates on BioCryst Pharmaceuticals' financial performance and operational status, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.

Are there any new material events disclosed under Regulation FD?

The filing states it includes 'Regulation FD Disclosure,' but the specific disclosures are not detailed in the provided text.

What types of financial statements and exhibits are included?

The filing mentions 'Financial Statements and Exhibits' are included, but the specific contents are not listed in the provided text.

When was this 8-K filed?

This 8-K was filed on November 4, 2024.

What is BioCryst Pharmaceuticals' principal business address?

BioCryst Pharmaceuticals' principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-11-04 07:06:59

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 4, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing recent corporate developments and its financial results for the third quarter ended September 30, 2024, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated November 4, 2024 entitled "BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: November 4, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing